RareKids-CAN: The New Pediatric Rare Disease Clinical Trials and Treatment Network
To ensure that every child, adolescent, and young adult in Canada affected by rare diseases has access to effective and innovative treatments.
Out of the 7,000 known rare diseases, only about 5% have specific treatments available. Patients and families often need to go to other countries and pay themselves for experimental treatments. RareKids-CAN wants to change this by supporting national and international clinical trials to make new discoveries and advance treatments for children, adolescents, young adults and their families here in Canada.
Funded in early 2024 by the Canadian Institutes of Health Research Institute of Genetics, as part of the Government of Canada’s National Strategy for Drugs for Rare Diseases investment, RareKids-CAN collaborates with patient/family partners, patient organizations, investigators, research networks, and industry partners to design, develop, set up, manage, and execute pediatric rare disease clinical trials in Canada.
To help develop and execute these cutting-edge clinical trials, the EnRICH Lab is involved and Dr. Offringa leads the RareKids-CAN Design and Methods Sub-Platform: https://www.rarekidscan.com/sub-platform-leads
Find Out More About RareKids-CAN
Updated August 2024